{
    "paper_id": "06fb93cb30ddd4cf8af3a3d56f1aa23e65fd5a80",
    "metadata": {
        "title": "Corresponding author(s)",
        "authors": [
            {
                "first": "Daniel",
                "middle": [
                    "E"
                ],
                "last": "Kaufmann",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Michel",
                "middle": [
                    "C"
                ],
                "last": "Nussenzweig",
                "suffix": "",
                "affiliation": {},
                "email": ""
            }
        ]
    },
    "abstract": [
        {
            "text": "The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Abstract"
        },
        {
            "text": "The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Abstract"
        },
        {
            "text": "All plots are contour plots with outliers or pseudocolor plots. A numerical value for number of cells or percentage (with statistics) is provided. Methodology Sample preparation Cryopreserved PBMCs were thawed, rested, stimulated, fixed, permeabilized and stained according to the demands on each experiment. All details are mentioned in the Methods section. Instrument LSRII (BD Biosciences) and LSR Fortessa (BD) for standard flow cytometry. Software Flow cytometry data were collected by DIVA 8.0.1 and analyzed with Flowjo v10 (Treestar).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Abstract"
        },
        {
            "text": "Cell population abundance For Flow Cytometry, we collected 0.1-15M events depending on the experiment. FMO controls and DMSO-treated controls were used as controls.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Abstract"
        }
    ],
    "body_text": [
        {
            "text": "For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Statistics"
        },
        {
            "text": "The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly",
            "cite_spans": [],
            "ref_spans": [],
            "section": "n/a Confirmed"
        },
        {
            "text": "The statistical test(s) used AND whether they are one-or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "n/a Confirmed"
        },
        {
            "text": "A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)",
            "cite_spans": [],
            "ref_spans": [],
            "section": "n/a Confirmed"
        },
        {
            "text": "For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "n/a Confirmed"
        },
        {
            "text": "Flow cytometry data were analyzed with Flowjo v10 (Treestar) and statistical analyses were performed with Prism v8 for Mac (Graphpad Software Inc). Amino acid alignments of intact gag sequences were obtained by using ClustalW v.2.1 under the BLOSUM cost matrix. Sequences with premature stop codons were excluded from all analyses. Maximum likelihood phylogenetic trees were then generated from these alignments using RAxML v.8.2.9 under the GTRGAMMA model with 1,000 bootstraps. To analyze changes between reservoir and rebound viruses, gag sequences were aligned at the amino acid level to a HXB2 reference using ClustalW v.2.1.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Data analysis"
        },
        {
            "text": "For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Data analysis"
        },
        {
            "text": "Policy information about availability of data All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Data"
        },
        {
            "text": "-Accession codes, unique identifiers, or web links for publicly available datasets -A list of figures that have associated raw data -A description of any restrictions on data availability",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Data"
        },
        {
            "text": "Sequences from all isolated viruses are available in GenBank, accession numbers MN750027 -MN750174. Additional datasets that support the findings of this study are available from the corresponding authors on reasonable request.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Data"
        },
        {
            "text": "October 2018",
            "cite_spans": [],
            "ref_spans": [],
            "section": "nature research | reporting summary"
        },
        {
            "text": "Field-specific reporting Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "nature research | reporting summary"
        },
        {
            "text": "For a reference copy of the document with all sections, see nature.com/documents/nr-reporting-summary-flat.pdf",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Life sciences Behavioural & social sciences Ecological, evolutionary & environmental sciences"
        },
        {
            "text": "All studies must disclose on these points even when the disclosure is negative.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Life sciences study design"
        },
        {
            "text": "No sample size calculation was performed. Results obtained from the bNAb+ATI clinical trial (NCT02825797) have been previously published in Mendoza et al., Nature 561, 479-484 (2018). Nine of the 15 study participants who fulfilled the study eligibility criteria harbored latent reservoir that was sensitive to both bNAbs (10-1074 and 3BNC117) and maintained viral suppression for 15 to >30 weeks after ART discontinuation. We analyzed all available study participants (n=9) with prolonged viral suppression for this manuscript.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Sample size"
        },
        {
            "text": "In addition, two study participants who harbored latent reservoir that was resistant to one of the two bNAbs and who rebounded early after ATI (week 5 or 7) were analyzed (Extended Data Figure 5 ).",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 186,
                    "end": 194,
                    "text": "Figure 5",
                    "ref_id": null
                }
            ],
            "section": "Sample size"
        },
        {
            "text": "The number of individuals included in the historical comparison group of people on continuous ART (n=13) was chosen to approximately match the number of participants enrolled into the Phase Ib trial.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Sample size"
        },
        {
            "text": "Data exclusions No participant fulfilling the criteria mentioned above was excluded from the analyses.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Sample size"
        },
        {
            "text": "Samples analyzed in this study were obtained from participants of a clinical trial (bNAb+ATI) or an observational study (ART) and samples were analyzed on individual study participants. Experiments did not include replicates as all participants and data points are unique. ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Replication"
        }
    ],
    "bib_entries": {
        "BIBREF0": {
            "ref_id": "b0",
            "title": "3BNC117 and 10-1074 are investigational anti-HIV-1 neutralizing antibodies manufactured for clinical use",
            "authors": [],
            "year": null,
            "venue": "They are being investigated under US FDA INDs 118225 and 123713",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF1": {
            "ref_id": "b1",
            "title": "All antibodies used for flow cytometry are listed in supplementary tables 1, 2 and 5, which describe the specific panels used",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF4": {
            "ref_id": "b4",
            "title": "CD8 APC-Fire750 SK1",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF7": {
            "ref_id": "b7",
            "title": "CD40L BV421, TRAP1, BD Biosciences 563886, lot#6280762, 5 \u03bcl/test",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF9": {
            "ref_id": "b9",
            "title": "CD107A BV786, H4A3, BD Biosciences 563869, lot#8144866, 5 \u03bcl/test",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF11": {
            "ref_id": "b11",
            "title": "BD Biosciences 550078, lot#8176503, 1 \u03bcl/test nature research | reporting summary October",
            "authors": [
                {
                    "first": "P",
                    "middle": [
                        "E"
                    ],
                    "last": "Mip1\u03b2",
                    "suffix": ""
                }
            ],
            "year": 2018,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "21--1351",
            "other_ids": {}
        },
        "BIBREF14": {
            "ref_id": "b14",
            "title": "CD69 BUV395, FN50, BD Biosciences 564364, lot#8242749, 5 \u03bcl/test",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF15": {
            "ref_id": "b15",
            "title": "CD137 (4-1BB) PE-Cy7",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF19": {
            "ref_id": "b19",
            "title": "PD-1 Alexa Fluor 647, EH12.2H7, Biolegend 329910, lot# B241533, 2.5 \u03bcl/test",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF22": {
            "ref_id": "b22",
            "title": "CD19 BUV737, SJ25C1, BD Biosciences 564303, lot#5100759, 3 \u03bcl/test",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF23": {
            "ref_id": "b23",
            "title": "1 \u03bcl/test Validation 3BNC117 and 10-1074 that were administered to the participants were manufactured by Celldex Therapeutics under Good Manufacturing Practice and have been fully characterized in terms of biophysical properties and potency (INDs 118225 and 123713)",
            "authors": [
                {
                    "first": "P",
                    "middle": [
                        "E"
                    ],
                    "last": "Hiv-1 Gag",
                    "suffix": ""
                },
                {
                    "first": "Kc57",
                    "middle": [],
                    "last": "",
                    "suffix": ""
                },
                {
                    "first": "Beckman",
                    "middle": [],
                    "last": "Coulter",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "They are being investigated under US FDA INDs 118225 and 123713",
            "volume": "6604667",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF24": {
            "ref_id": "b24",
            "title": "All antibodies used for flow cytometry were commercially available. Clones and companies are listed in the supplementary tables 1, 2 and 5",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF25": {
            "ref_id": "b25",
            "title": "CD3 BUV395, reactivity: human (QC testing, BD Biosciences), application: flow cytometry (routinely tested",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF26": {
            "ref_id": "b26",
            "title": "CD4 BUV496, reactivity: human (QC testing, BD Biosciences), application: flow cytometry (routinely tested",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF27": {
            "ref_id": "b27",
            "title": "CD8 APC-Fire750, reactivity: human (Biolegend), application: flow cytometry (quality tested, Biolegend) 4.CD14 BV510, reactivity: human (Biolegend), application: flow cytometry (quality tested",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF28": {
            "ref_id": "b28",
            "title": "CD19 BV510, reactivity: human (Biolegend), application: flow cytometry (quality tested",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF29": {
            "ref_id": "b29",
            "title": "CD40L BV421, reactivity: human (QC testing, BD Biosciences), application: flow cytometry (routinely tested",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF30": {
            "ref_id": "b30",
            "title": "CD56 BUV737, reactivity: human (QC testing, BD Biosciences), application: flow cytometry (routinely tested",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF31": {
            "ref_id": "b31",
            "title": "CD69 PerCP-eFluor710, reactivity: human (ThermoFisher), tested applications: flow cytometry",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF32": {
            "ref_id": "b32",
            "title": "CD107A BV786, reactivity: human (QC testing, BD Biosciences), application: flow cytometry (routinely tested",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF33": {
            "ref_id": "b33",
            "title": "reactivity: human (QC testing, BD Biosciences), application: flow cytometry (routinely tested, BD Biosciences) 11. IL-2 PE-Dazzle594, reactivity: human (Biolegend), application: flow cytometry (quality tested",
            "authors": [
                {
                    "first": "Pe-Cy7",
                    "middle": [],
                    "last": "Ifn\u03b3",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF34": {
            "ref_id": "b34",
            "title": "reactivity: human (QC testing, BD Biosciences), application: flow cytometry (routinely tested",
            "authors": [
                {
                    "first": "P",
                    "middle": [
                        "E"
                    ],
                    "last": "Mip1\u03b2",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF35": {
            "ref_id": "b35",
            "title": "TNF\u03b1 APC, reactivity: human (QC testing, BD Biosciences), application: flow cytometry (routinely tested, BD Biosciences) 14. CD3 PerCP-eFluor710, reactivity: human (ThermoFisher), tested applications: flow cytometry (Thermofisher) 15. CD8 BV711, reactivity: human (Biolegend), application: flow cytometry (quality tested",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF36": {
            "ref_id": "b36",
            "title": "CD69 BUV395, reactivity: human (QC testing, BD Biosciences), application: flow cytometry (routinely tested, BD Biosciences) 17. CD137 (4-1BB) PE-Cy7, reactivity: human (Biolegend), application: flow cytometry (quality tested, Biolegend) 18. PD-L1 BV421, reactivity: human (Biolegend), application: flow cytometry (quality tested",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF37": {
            "ref_id": "b37",
            "title": "reactivity: human (ThermoFisher), tested applications: flow cytometry",
            "authors": [
                {
                    "first": "",
                    "middle": [],
                    "last": "Hla-Dr Apc-Efluor780",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF38": {
            "ref_id": "b38",
            "title": "CD38 PE, reactivity: human (QC testing, BD Biosciences), application: flow cytometry (routinely tested, BD Biosciences) 21. PD-1 Alexa Fluor 647, reactivity: human (Biolegend), application: flow cytometry (quality tested, Biolegend) 22. CD4 PE-Cy7, reactivity: human (QC testing, BD Biosciences), application: flow cytometry (routinely tested, BD Biosciences) 23. CD14 BUV737, reactivity: human (QC testing, BD Biosciences), application: flow cytometry (routinely tested, BD Biosciences) 24. CD19 BUV737, reactivity: human (QC testing, BD Biosciences), application: flow cytometry (routinely tested, BD Biosciences) 25. HIV-1 Gag PE, reactivity: HIV-1 core antigen",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF39": {
            "ref_id": "b39",
            "title": "Eligible participants for the bNAb clinical trial were adults aged 18-65 years, HIV-1-infected, on ART for a minimum of 24 months, with plasma HIV-1 RNA levels of 50 copies/ml for at least 18 months (one viral blip of >50 but <500 copies/ml during this 18-month period was allowed), plasma HIV-1 RNA levels of <20 copies/ml at the screening visit, and a current CD4+ T cell count >500 cells/\u03bcl",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF40": {
            "ref_id": "b40",
            "title": "To study HIV-specific T cell responses during ART suppression, individuals were recruited at Rockefeller University, that were on ART for at least 4 years. Clinical data for these individuals are shown in extended data figure 2",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF41": {
            "ref_id": "b41",
            "title": "Recruitment Participants of the bNAb+ATI trial were pre-screened for sensitivity of latent proviruses against 3BNC117 and 10-1074 antibodies by bulk PBMC viral outgrowth. Sensitivity was defined as an IC50 < 2 \u03bcg/ml for both antibodies against outgrowth virus. Participants harboring sensitive viruses were invited for screening and were enrolled in the study sequentially",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF42": {
            "ref_id": "b42",
            "title": "HIV-infected individuals on continuous ART were recruited at the Rockefeller University",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        }
    },
    "ref_entries": {
        "FIGREF0": {
            "text": "Give P values as exact values whenever suitable.For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settingsFor hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes Estimates of effect sizes (e.g. Cohen's d, Pearson's r), indicating how they were calculated Our web collection on statistics for biologists contains articles on many of the points above.",
            "latex": null,
            "type": "figure"
        },
        "TABREF0": {
            "text": "Randomization The bNAb+ATI clinical trial was single arm.The bNAb+ATI clinical trial was open label.Reporting for specific materials, systems and methodsWe require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.",
            "latex": null,
            "type": "table"
        }
    },
    "back_matter": [
        {
            "text": "No potential self-selection bias or other bias are known.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "October 2018"
        },
        {
            "text": "The clinical trial protocol was approved by the Federal Drug Administration in the USA, the Paul-Ehrlich-Institute in Germany, and the Institutional Review Boards (IRBs) at the Rockefeller University and the University of Cologne. The protocol for collection of samples from ART-suppressed participants was approved by the Rockefeller University IRB.Note that full information on the approval of the study protocol must also be provided in the manuscript. ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Ethics oversight"
        },
        {
            "text": "All primary and secondary outcomes of the trial are described under https://clinicaltrials.gov/ct2/show/NCT02825797. For the immunological exploratory substudy presented here, we pre-selected participants with a specific outcome (maintained viral suppression for >12 weeks after analytical treatment interruption).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Outcomes"
        }
    ]
}